Accelerated Technology Laboratories, Inc. (ATL) and Institute for Biopharmaceutical Research (IBR, Inc.) Partner to Provide Pipette Calibration Solutions for GLP and GMP Compliant Laboratories
News Aug 13, 2013
Accelerated Technology Laboratories, Inc. (ATL), a premier supplier of Laboratory Data Management Solutions, has announced a new partnership with Institute for Biopharmaceutical Research (IBR, Inc.) - a leader in turnkey calibration software.
ATL is the North American Partner for IBR and will be offering Check&Track v2.0 to GLP and GMP compliant laboratories. Check&Track v2.0 offers just-in-time management of certification and recordkeeping for pipettes, specific to ISO 9000, ISO 8655, DIN 12650 and NCCLS requirements. Key benefits of this technology include automatic collection of data from an RS232 balance, automatic calibration procedures (manufacturer specific and custom macros), guided data collection during calibration, online input for environmental parameters, automatic statistics and qualification according to the specifications of the manufacturer, complete pipette history, schedules for pipette's calibration and balance service administration.
"ATL is excited for the opportunity to team up with IBR for tighter integration of our complementary
products. They share our passion for automation and providing best-of-class tools, allowing customers to be more productive and efficient," said Dr. Christine Paszko, ATL's Vice President of Sales and Marketing.
"IBR is proud having found ATL as a highly professional partner for his software Check &Track and appreciates the fascinating collaboration dedicated to convert emerging needs in the quality managed laboratory to sophisticated products," said Dr. René Moser, IBR's CEO and CSO.
HIV-1 replicates in ninja-like ways. The virus slips through the membrane of vital white blood cells. Inside, HIV-1 copies its genes and scavenges parts to build a protective bubble for its copies. Now, supercomputers have helped model a key building block in the HIV-1 protective capsid, which could lead to strategies for potential therapeutic intervention in HIV-1 replication.READ MORE